KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.

ABSTRACT:

Background

Kirsten Rat Sarcoma (KRAS) copy number amplification has emerged as an oncogenic driver in colorectal cancer (CRC), in addition to KRAS mutation. However, its clinical significance remains poorly understood. Notably, CRC patients with wild-type KRAS but harboring KRAS amplification have shown resistance to anti-EGFR therapy, representing an unmet clinical need.

Methods

In this study, we comprehensively investigated the impact of KRAS amplification-alone and in conjunction with mutation-on clinicopathological characteristics, immune infiltration, and therapeutic response. KRAS copy number variation (CNV) was classified into amplification and non-amplification groups. KRAS mutational status was determined as wild-type (WT) or mutant (MUT) using qPCR and Sanger seque

SUBMITTER: Yang X 

PROVIDER: S-EPMC12291525 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature